Xhosa
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Iintlobo zeemveliso
iveliso ezifakiwe
Iipilisi zeLenopril ezixhobisa uLawulo lweGazi kunye nempilo ye-Cardiovascular Health

Iipilisi zeLenopril ezixhobisa uLawulo lweGazi kunye nempilo ye-Cardiovascular Health
I-Telmisartan Ingcono i-antihypertensive Ukukhusela izintso

I-Telmisartan Ingcono i-antihypertensive Ukukhusela izintso
I-Flumazenil I-Antagonist ekhethiweyo ye-GABAA ye-Receptor kunye nezicelo zayo zonyango

I-Flumazenil I-Antagonist ekhethiweyo ye-GABAA ye-Receptor kunye nezicelo zayo zonyango
I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers

I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers
I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers

I-Dabrafenib Unyango olujolisiweyo lwe-BRAF-Mutated Cancers
I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic

I-Tirzepatide Dual GLP-1 kunye ne-GIP Receptor Agonist yoLawulo lobunzima kunye noLawulo lweGlycemic
Cisapride Gastric Stimulant for Indigestion and Digestive Disorders

Cisapride Gastric Stimulant for Indigestion and Digestive Disorders
I-YK-11 ye-SARM enamandla kwiZakhiwo zeMuscle, iiNgeniso zamandla, kunye ne-Myostatin Inhibition

I-YK-11 ye-SARM enamandla kwiZakhiwo zeMuscle, iiNgeniso zamandla, kunye ne-Myostatin Inhibition
I-Ostarine (MK-2866) i-SARM eNqabileyo yokuKhula kweMuscle, ukuLahla kwaManqatha, kunye nokuBuyiswa koMzimba

I-Ostarine (MK-2866) i-SARM eNqabileyo yokuKhula kweMuscle, ukuLahla kwaManqatha, kunye nokuBuyiswa koMzimba
I-MK-677 i-Compound ekhethekileyo yokuKhula kweZihlunu, ukunyamezela, kunye nokuBuyisa

I-MK-677 i-Compound ekhethekileyo yokuKhula kweZihlunu, ukunyamezela, kunye nokuBuyisa
0102030405
I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers
I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers

I-Trametinib Kinase Inhibitor Ijolise kwi-BRAF V600 yoGuquko-Positive Cancers

Ixabiso lokubhekisela: USD 8-15 / g

  • Igama lemveliso Trametinib
  • Inombolo yeCAS. 871700-17-3
  • MF I-C26H23FIN5O4
  • MW 615.402623
  • Ukuxinana 1.743
  • Indawo yokunyibilika 293-303°C
Qhagamshelana nathi
iinkcukacha zemveliso

Inkcazo eneenkcukacha

I-Trametinib inamandla kwaye i-kinase inhibitor ekhethiweyo esetyenziswa ngokukodwa kunyango lwe-melanoma engabonakaliyo okanye i-metastatic kunye ne-BRAF V600 mutation, kunye neentlobo ezithile ze-Advanced or Metastatic non-small cell lung cancer. Eli nqaku liphonononga indlela yokusebenza, izalathiso zeklinikhi, kunye noncedo lwetrametinib kunyango lwe-BRAF V600 yomhlaza wenguqu eguqukileyo.

I. Ukuqonda iTrametinib:
A. Umlomo, onamandla, kunye ne-kinase inhibitor ekhethiweyo
B. Kukwiklasi ye-MEK inhibitors
C. Ivimbela umsebenzi we-kinase we-MEK1 kunye ne-MEK2
D. Inqanda umlambo we-ERK1 kunye nomqondiso we-ERK2

II. Iimpawu zoNyango:
A. Ayichaswanga okanye imetastatic melanoma egcina iBRAF V600 ukuguqulwa:
Unyango oludityanisiweyo kunye ne-dabrafenib mesylate
B. Unyango lwe-postoperative adjuvant ye-BRAF V600 mutation-positive melanoma:
Unyango lwe-Adjuvant kunye ne-dabrafenib mesylate emva kokutshatyalaliswa ngokupheleleyo

17161152266097be

III. Indima kuMhlaza weMiphunga yeSeli engeNcinane:

A. Umhlaza wemiphunga weseli ongengowona mncinci njengoyena nobangela uphambili wokugula nokufa

B. Izinga lokuguqulwa kofuzo lwe-BRAF kunye nokuxhaphaka kwe-BRAF V600E yokuguqula

C. Trametinib's inhibitory effect kwi-BRAF V600 mutation-positive melanoma cells


IV. Indlela yokwenza:

A. Uthintelo olubuyiselwayo lwe-mitogen-activated extracellular signal-regulated kinase (MEK) 1 kunye ne-MEK2

B. Impembelelo kwindlela ye-MAPK kunye neprotheni ye-MEK

C. Ukuthintela ukwanda kweeseli kunye nomzila we-ERK osezantsi


V. Unyango lwe-Adjuvant emva kokuhlinzwa:

A. Inzuzo yonyango olujoliswe kuyo oludityanisiweyo kunye neDabrafenib kunye neTrametinib

B. Ixesha elide, ixesha elide, ixesha elide lokuphinda-phinda ukusinda (RFS) izibonelelo kwinqanaba eliphezulu lomngcipheko III BRAF mutation-positive melanoma izigulane.



I-Trametinib, i-kinase inhibitor ekujoliswe kuyo, ibonisa ukusebenza kakuhle kunyango lwe-BRAF V600 yomhlaza we-mutation-positive, ngokukodwa i-melanoma engaguqukiyo okanye ye-metastatic kunye neentlobo ezithile zomhlaza wemiphunga weseli engeyincinci. Indlela yokusebenza kwayo, inqanda umsebenzi we-MEK1 kunye ne-MEK2 kinase, ikhokelela ekuthinteleni kwendlela ye-ERK esezantsi kunye nokunyanzeliswa kwe-cell proliferation. I-Trametinib, idityaniswe ne-dabrafenib mesylate, ibonelela ngeenzuzo zonyango kuzo zombini iisetingi ezikwinqanaba eliphezulu kunye ne-adjuvant kwi-BRAF V600 izigulane ze-melanoma eziguqukayo.
Qhagamshelana nathi ngeengcebiso zamayeza kunye nolwazi lwamaxabiso ehoseyile ukomeleza ukhathalelo lwezigulane.

Inkcazo

171611254334271z